Eligix Frequently Asked Questions (FAQ)
Where is Eligix's headquarters?
Eligix's headquarters is located at 200 Boston Avenue, Medford.
What is Eligix's latest funding round?
Eligix's latest funding round is Acquired.
How much did Eligix raise?
Eligix raised a total of $33.7M.
Who are the investors of Eligix?
Investors of Eligix include Biotransplant, Advanced Technology Ventures, Adams Street Partners, Crown Advisors, InterWest Partners and 3 more.
Who are Eligix's competitors?
Competitors of Eligix include InvivoSciences, Amnis Corporation, Aileron Therapeutics, WaferGen Bio-systems, Inotek Pharmaceuticals and 7 more.
Compare Eligix to Competitors
Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
Innoprot tGFP-BACE1 HEK293 Cell Line CB2 Internalization Assay Cell Line hGR Nuclear Translocation Assay Cell Line Human Cardiac Myocytes Assay Development Neurotoxicity Assay induced by beta amyloid NEWS Innoprot has been awarded on the Bizkaia Ekinez Prizes 05/06/2009 Innoprot has been awarded on the Bizkaia Ekinez Prizes with the "Gaztedi Prize"
InvivoSciences is a precision medicine company operating in the drug development and life sciences research sectors. The company's main offerings include the development of patient-derived and gene-edited human samples, specifically functional 3D engineered micro-human heart tissue platforms, which are used to personalize the drug development process. These platforms, combined with the company's integration of cell and tissue handling automation, tissue phenotyping assays, and computational biology, enable the rapid identification of safety and efficacy profiles of treatments for specific patient groups. It was founded in 2001 and is based in Wauwatosa, Wisconsin.
RenaMed Biologics, a University of Michigan spin-out from the late 90s, is a clinical stage cellular therapy company dedicated to the design, development, and commercialization of human cell replacement systems. RenaMed's products provide targeted and kidney cell therapy for patients suffering from severe inflammatory disease states such as Acute Renal Failure.
Entegrion is a life sciences development company specializing in technologies that support preserve the function of the human vascular system. The company's technologies are designed to overcome limitations in temperature, storage, safety, and availability of blood-derived products while improving functionality. The company was founded in 2002 and is based in Durham, North Carolina.
Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development